The invention discloses a kit for quantitatively detecting
methylation of an FOXK1
gene promoter region and application of the kit to identification of hysteromyoma and hysterosarcoma, the sequence of the FOXK1
gene promoter region is chr7: 4682295-4685295, the
reference genome version is GRCh37 / hg19, and the FOXK1
gene promoter region has a
nucleotide sequence shown in SEQ ID NO.1. The FOXK1 gene promoter region has a
nucleotide sequence shown in SEQ ID NO.2. The FOXK1 gene promoter region has a
nucleotide sequence shown in SEQ ID NO.2. The kit comprises a pair of primers FOXK1-Me-F and FOXK1-Me-R for detecting the
methylation degree of the FOXK1 gene and a probe FOXK1-Me-Probe, a pair of primers FOXK1-unMe-F and FOXK1-unMe-R for detecting the non-
methylation degree of the FOXK1 gene and a probe FOXK1-unMe-Probe, and a pair of primers B2M-F and B2M-R for a
reference gene B2M and a probe B2M-Probe. By detecting a specific gene methylation marker of cfDNA in
peripheral blood and particularly utilizing an MS-qPCR technology, the invention provides a non-invasive or minimally invasive early
differential diagnosis method for uterine
sarcoma, which is high in sensitivity, relatively simple and convenient to operate and controllable in cost. The method is helpful for distinguishing benign and malignant lesions before an operation, provides an important basis for
clinical decision making, avoids unnecessary operation risks, and improves prognosis of a patient.